Evidence map›Paper›PMID 38539106›Full record

ArticleBMC bioinformatics2024

SurvConvMixer: robust and interpretable cancer survival prediction based on ConvMixer using pathway-level gene expression images.

Shuo Wang, Yuanning Liu, Hao Zhang, Zhen Liu

Abstract read
In one paragraph

Article in BMC bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shuo Wang *College of Computer Science and Technology, Jilin University, Qianjin Street, Changchun, 130012, Jilin, China. shuowang0114@163.com.
Yuanning Liu *College of Computer Science and Technology, Jilin University, Qianjin Street, Changchun, 130012, Jilin, China.
Hao ZhangCollege of Computer Science and Technology, Jilin University, Qianjin Street, Changchun, 130012, Jilin, China.
Zhen LiuGraduate School of Engineering, Nagasaki Institute of Applied Science, Nagasaki, Japan.

Funding

Industrial Innovation Funds of Jilin Province of China No.2019C053-2National Key Research and Development Program of China No.2020-151National Natural Science Foundation of China No.62072210Natural Science Foundation of Jilin Province No.YDZJ202101ZYTS144
6 · The paper itself

Abstract

Cancer is one of the leading causes of deaths worldwide. Survival analysis and prediction of cancer patients is of great significance for their precision medicine. The robustness and interpretability of the survival prediction models are important, where robustness tells whether a model has learned the knowledge, and interpretability means if a model can show human what it has learned. In this paper, we propose a robust and interpretable model SurvConvMixer, which uses pathways customized gene expression images and ConvMixer for cancer short-term, mid-term and long-term overall survival prediction. With ConvMixer, the representation of each pathway can be learned respectively. We show the robustness of our model by testing the trained model on absolutely untrained external datasets. The interpretability of SurvConvMixer depends on gradient-weighted class activation mapping (Grad-Cam), by which we can obtain the pathway-level activation heat map. Then wilcoxon rank-sum tests are conducted to obtain the statistically significant pathways, thereby revealing which pathways the model focuses on more. SurvConvMixer achieves remarkable performance on the short-term, mid-term and long-term overall survival of lung adenocarcinoma, lung squamous cell carcinoma and skin cutaneous melanoma, and the external validation tests show that SurvConvMixer can generalize to external datasets so that it is robust. Finally, we investigate the activation maps generated by Grad-Cam, after wilcoxon rank-sum test and Kaplan-Meier estimation, we find that some survival-related pathways play important role in SurvConvMixer.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMelanomaSkin NeoplasmsGene ExpressionHumansGene expression dataInterpretable machine learningPathways in cancerRobustnessSurvival prediction

Identifiers

PMID38539106
PMCPMC10967213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.